Imfinzi (durvalumab)

P1/2, N=50, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2026

P2, N=51, Active, not recruiting, The Methodist Hospital Research Institute | N=39 --> 51 | Trial completion date: Dec 2025 --> Dec 2028

P1, N=25, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Feb 2026 --> Feb 2027 | Trial completion date: Feb 2026 --> Feb 2027

P1/2, N=85, Recruiting, Mayo Clinic | Trial completion date: Feb 2028 --> Aug 2029 | Trial primary completion date: Aug 2027 --> Aug 2029

P2, N=99, Recruiting, Mayo Clinic | Trial completion date: May 2031 --> May 2027 | Trial primary completion date: May 2031 --> May 2027

P2/3, N=203, Recruiting, University College London | Not yet recruiting --> Recruiting

The case underscores current controversies in the management of stage III NSCLC and the critical role of the MDT. While neoadjuvant and perioperative chemo-immunotherapy offers an opportunity for less extensive surgical resection and improved oncological outcomes, this strategy is not without risks and validated biomarkers to guide decision making are lacking. Concurrent chemoradiotherapy (cCRT) followed by durvalumab remains the standard for fit patients with unresectable or inoperable stage III disease. Future progress depends on clinical trials, biomarker development, and real-world data collection and national audits.

Savolitinib plus durvalumab shows OS in MET-driven PRC, supporting the ongoing SAMETA RIII trial (ClinicalTrials.gov identifier: NCT05043090). ctDNA may be a useful predictive biomarker.

Natural killer cells showed only a limited contribution to the killing of HNSCC cells pretreated with RT or RT + DDRi. However, a subset of patients with head and neck tumors-such as those represented by the HSC4 model-might still benefit from combining RT with ATMi rather than ATRi to enhance NK cell-mediated tumor killing.

Key advances include: (1) In bladder cancer, perioperative durvalumab (NIAGARA) and enfortumab vedotin plus pembrolizumab (KEYNOTE-905/EV-303) set new standards, while HER2-targeted disitamab vedotin plus toripalimab (RC48-C016) improved metastatic survival...(3) In prostate cancer, enzalutamide plus leuprolide improved survival in high-risk biochemical recurrence (EMBARK). Capivasertib plus abiraterone benefited PTEN-deficient metastatic hormone-sensitive disease (CAPItello-281). The PSMAddition trial demonstrated that adding [177Lu]Lu-PSMA-617 to standard therapy significantly improved radiographic PFS in PSMA-positive mHSPC. Docetaxel scheduling was optimized (ARASAFE), and an AI model (STAMPEDE) identified patients for AR inhibitor benefit. Novel agents like saruparib and pasritamig showed promise...The 2025 evidence establishes multiple new standards of care across GU cancers, emphasizing biomarker-driven strategies, immunotherapy integration, novel resistance mechanisms, and treatment optimization. This synthesis provides an evidence-based framework for updating guidelines and highlights the move toward more personalized management, while noting persistent challenges and future research needs.

PACCELIO is a multinational, multicenter, randomized, phase II trial comparing the safety and efficacy of FDG-PET/CT based, volume-reduced, hypofractionated CRT with consolidation durvalumab to standard-volume, conventionally fractionated CRT with consolidation durvalumab in inoperable stage III NSCLC...Clinicaltrials.gov identifier: NCT06102057 (Date of initial registration: 26th October 2023), https://clinicaltrials.gov/study/NCT06102057. The online version contains supplementary material available at 10.1186/s12885-026-15901-x.

P1, N=40, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting